Pharm small group: HIV 2

Question 1

What is the MOA of protease inhibitors?

Answer 1

Prevent processing of viral proteins -> production of immature, noninfectious viral particles.

Question 2

Are protease inhibitors active against HIV-2?

Answer 2

Yes… active against both HIV-1 and HIV-2.

Question 3

Do protease inhibitors need intracellular activation?

Answer 3

No

Question 4

What are the adverse effects associated with protease inhibitors?

Answer 4

Carbohydrate and Lipid metabolism disorders:

1) Hyperglycemia
2) Insulin resistance
3) Hyperlipidemia
4) Altered body fat distribution
5) Buffalo hump
6) Gynecomastia
7) Truncal obesity may occur with facial and peripheral lipodystrophy

Question 5

Protease inhibitors are extensively metabolized by what?

Answer 5

CYP3A4

Question 6

Which protease inhibitor is used as a pharmacokinetic enhancer due to its potent CYP3A4 inhibitory properties?

Answer 6

Ritonavir

Question 7

Which anti-retroviral is an entry inhibitor? (2)

Answer 7

1) Enfuvirtide

2) Maraviroc

Question 8

What is the A.E. of enfuvirtide?

Answer 8

local injection site reactions

Question 9

What is the MOA of Raltegravir?

Answer 9

Inhibits integrase -> prevents integration of reverse transcribed HIV DNA into chromosomes of host cells

Question 10

What are the adverse effects of Raltegravir?

Answer 10

1) Diarrhea
2) Nausea
3) Dizziness
4) Headache
5) Increases in creatine kinase

Question 11

What is the preferred HIV regimen for a pregnant woman?

Answer 11

Lopinavir +
Low dose Ritonavir +
Zidovudine +
Lamivudine

Question 12

What is the preferred NNRTI based regimen?

Answer 12

Efavirenz +
Tenofovir +
Emtricitabine

Question 13

What is the preferred PI-based regimen?

Answer 13

Atazanavir OR Darunavir
+
Low Dose Ritonavir + Tenofovir + Emtricitabine

Question 14

What is the preferred regimen for occupational post-exposure prophylaxis

Answer 14

Raltegravir + Tenogovir + Emtricitabine

for 28 days